This proposal is a sent in response to RFA #HD-01-003 to continue funding of a Pediatric Pharmacology Research Unit at Children's Mercy Hospitals and Clinics (CMH) in Kansas City, Missouri as one of the sites within the NICHD Network of PPRU's. The overall objectives of the Unit are: 1) to continue and expand collaborative participation of the CMH PPRU in the PPRU Network for the primary purpose of producing data that will support labeling of drugs for children through the creation of new information and knowledge;and 2) To conduct basic and translational research in developmental pharmacology that will advance our understanding of the impact of genetic- age- and disease-related differences in drug disposition and action (both beneficial and adverse).
Specific Aims i nclude: 1) The collaborative conduct of studies of new and currently marketed drugs with priority given to PPRU Network studies;2) The identification, collation, analysis, and interpretation of data from pediatric clinical trials that are sufficient for expansion of pediatric labeling;3) Use of molecular approaches to define the """"""""link"""""""" between childhood development, disease expression, drug biotransformation and drug action;4) Use of bioinformatics, pharmacogenomics, metabolomics to explore and define the basis of developmental regulation of important drug metabolizing enzymes and transporters;5) The provision of a unique teaching environment in which pediatricians, medical sub-specialists, clinical pharmacists, nurses and allied health care professionals can gain expertise in clinical investigation and the discipline of pediatric clinical pharmacology. The capability of the investigators and applicant institution to accomplish these objectives and specific aims is demonstrated by: I) effective programmatic composition and administration;2) expertise and resources within the applicant institution;3) previous and current research accomplishments related to the PPRU Network;4) projected programmatic expansion necessary to meet the anticipated increased demands for pediatric clinical trials over the next five years and also, to enhance the integration of translational science into the drug development process;and 5) presentation of two new research proposals which speak directly to the program objectives and are ideally suited for conduct as part of the PPRU Network.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10HD031313-16S3
Application #
8010814
Study Section
Special Emphasis Panel (ZHD1-DSR-A (01))
Program Officer
Giacoia, George
Project Start
1994-01-01
Project End
2010-12-31
Budget Start
2009-01-01
Budget End
2010-12-31
Support Year
16
Fiscal Year
2010
Total Cost
$126,225
Indirect Cost
Name
Children's Mercy Hosp (Kansas City, MO)
Department
Type
DUNS #
073067480
City
Kansas City
State
MO
Country
United States
Zip Code
64108
Jones, Bridgette L; Kearns, Gregory; Neville, Kathleen A et al. (2013) Variability of histamine pharmacodynamic response in children with allergic rhinitis. J Clin Pharmacol 53:731-7
Myers, Angela L; Gaedigk, Andrea; Dai, Hongying et al. (2012) Defining risk factors for red man syndrome in children and adults. Pediatr Infect Dis J 31:464-8
Cohen-Wolkowiez, Michael; Poindexter, Brenda; Bidegain, Margarita et al. (2012) Safety and effectiveness of meropenem in infants with suspected or complicated intra-abdominal infections. Clin Infect Dis 55:1495-502
Jones, B L; Kearns, G L (2011) Histamine: new thoughts about a familiar mediator. Clin Pharmacol Ther 89:189-97
Smith, P Brian; Cohen-Wolkowiez, Michael; Castro, Lisa M et al. (2011) Population pharmacokinetics of meropenem in plasma and cerebrospinal fluid of infants with suspected or complicated intra-abdominal infections. Pediatr Infect Dis J 30:844-9
Ward, Robert M; Kearns, Gregory L; Tammara, Brinda et al. (2011) A multicenter, randomized, open-label, pharmacokinetics and safety study of pantoprazole tablets in children and adolescents aged 6 through 16 years with gastroesophageal reflux disease. J Clin Pharmacol 51:876-87
Price, K E; Pearce, R E; Garg, U C et al. (2011) Effects of valproic acid on organic acid metabolism in children: a metabolic profiling study. Clin Pharmacol Ther 89:867-74
Newland, Jason G; Kearns, Gregory L (2008) Treatment strategies for methicillin-resistant Staphylococcus aureus infections in pediatrics. Paediatr Drugs 10:367-78
Kearns, Gregory L; Lu, Susan; Maganti, Lata et al. (2008) Pharmacokinetics and safety of montelukast oral granules in children 1 to 3 months of age with bronchiolitis. J Clin Pharmacol 48:502-11
Abdel-Rahman, Susan M; Benziger, David P; Jacobs, Richard F et al. (2008) Single-dose pharmacokinetics of daptomycin in children with suspected or proved gram-positive infections. Pediatr Infect Dis J 27:330-4

Showing the most recent 10 out of 36 publications